Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapyInvivoscribe Marketing2021-02-11T20:11:02-08:00October 8th, 2020|2020 Publications, Publications| Read more
Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)Invivoscribe Marketing2021-02-12T00:14:15-08:00August 9th, 2017|2017 Publications, Publications| Read more